Interview Intersection: Expert Interviews From March 2026

Clinical Updates

The Hassle Stops Here: Icotrokinra Takes Aim at Psoriasis Care Gaps

• MORE ON ICOTROKINRA: The Dawn of Oral Peptides: Linda Stein Gold, MD, FAAD, on the FDA Approval of Icotrokinra

Only 15–20% of eligible patients currently receive systemic psoriasis treatment, and specialists believe icotrokinra's simplicity could meaningfully move that needle.

Breaking Down Zasocitinib Data at AAD 2026

Study investigator Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Red Light PDT Advances Field Therapy for Actinic Keratoses

• MORE FROM ROSSI: Anthony Rossi, MD, FAAD, FACMS, on the Practical Benefits of Photodynamic Therapy

Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.

AdvanceAD-Tx Gene Expression Profile Test May Help Guide Systemic Therapy Selection in Atopic Dermatitis

• MORE FROM LABWOHL: Determining Biologic or JAKi Efficacy for Patients With Moderate to Severe AD Through GEP Testing

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

AAD 2026: Intratumoral PH762 Shows Early Efficacy in Cutaneous SCC With No Immune-Related Adverse Events

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.

Reactivating the Follicle: PP405 Moves Toward Late-Stage Trials for Alopecia

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

Late-Breaking Data: Tape Strip Profiling Reveals Divergent Molecular Pathways in Skin Aging

• MORE LATE BREAKERS: Late-Breaking Data: Roflumilast Cream 0.05% Demonstrates Efficacy and Favorable Tolerability in Infantile Atopic Dermatitis, AAD 2026 Late-Breaker: Lawrence Eichenfield, MD, on Phase 2 Success of Nemolizumab in Pediatric AD

At AAD 2026, Helen He, MD, highlights how minimally invasive molecular profiling distinguishes photoexposed and photoprotected aging trajectories.

Unique Perspectives

Derm Dash at Winter Clinical Miami 2026 with James Del Rosso, DO

James Del Rosso, DO, shares rapid-fire insights on mentorship, HS advances, contact dermatitis triggers, and teen skin care marketing concerns.

Effective Pediatric Dermatology Solutions Without the Insurance Hurdles

At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.

The Cutaneous Connection: By the Skin of Your Teeth with The Spizuoco Sisters

Twin experts reveal how dermatology and dentistry team up for facial aesthetics, early lesion detection, and safer care—from lasers to oral screenings.

Executive Insights: Extended-Release Oral Minoxidil Shows Optimized Pharmacokinetics and Potential to Enhance Hair Growth

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

Conference Insights

Nicholas Brownstone, MD, on Collaborative Immunology and Digital Education at Winter Clinical Miami

Nicholas Brownstone, MD, showcased multidisciplinary collaboration and educational podcast initiatives aimed at supporting both dermatology trainees and patients.

Skin of Color Society Meeting Reinforces Leadership, Mentorship, and Equity at AAD 2026

• MORE FROM AAD: Early Career Engagement and Innovation Take Center Stage at AAD 2026, Darrell Rigel, MD, MS’s Melanoma Updates from AAD 2026, Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis, Defining High-Risk NMSC: Integrating Staging Systems and Tumor Biology to Guide Management, Precision and Progress: Key Updates in Skin Cancer Prevention, Diagnosis, and Management

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Previewing the Inaugural PANP360 Immersive Conference with Co-Chair Izabela Horzempa, PA-C

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

Reflections and Looking Ahead

Thinking Outside the Box: Diego Ruiz Dasilva, MD, FAAD, on the Power of Case-Based Combo Therapy

Ruiz Dasilva emphasized case-based strategies for managing complex inflammatory dermatoses, highlighted chronic pruritus as an urgent unmet need, and called for more standardized designs for atopic dermatitis trials.

Derm Dispatch: How New PAs Can Navigate the Dermatology Job Market

• MORE DERM DISPATCH: Derm Dispatch: The Gut-Skin Axis Moves From Fringe to Front Lines, Derm Dispatch: The Modern Utility of Sodium Hypochlorite and Hypochlorous Acid Beyond the Bleach Bath

Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.

DermGPT: Beyond AI Search in Dermatology

• MORE FROM KAMANGAR: AI as a Workflow Tool, Not a Decision Maker

When used thoughtfully, AI transforms generic processes into innovative, time-saving clinical tools.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.